Translational Research

• When CT is needed for Luminal Advanced Breast Cancer
• Reprogramming human T cell circuitry
• Biomarker assessment for other I-O therapy (non-PD1)
• Agonist immunomodulatory monoclonal antibodies
• Immunosuppression in primary brain tumors
• Phenoptics: Immuno-profiling and phenotyping of multiple immune cell subsets in situ in FFPE tissue sections
• Spatially correlated high-plex protein (~ 100-plex) and high-plex mRNA (~ 1000-plex) profiling on FFPE tissue using Digital Spatial Profiling micro...
• TCR sequencing
• Arginase inhibition to modulate the TME: Rationale and early clinical experience
• ImmTACTM Platform: Novel bispecific high affinity TCR-effector fusions to modulate the immune system for the treatment of cancer
• Directing the immune system with neoantigen therapeutics
• Conditionally active antibodies for immunotherapy
• Generation of bio-specific antibodies with several targets
• ADU-S100 (MIW815), a first-in-class STING agonist
• Genomics response assessment
• Tracking T cell evolution in cancer
• High-dimensional profiling of human antigen-specific T cells: Asking T cells about what they “see” in cancer
• Immune cells in the tumour microenvironment
• Biomarker development in the lung cancer combination therapy space
• Genetic Counselling and Testing
• How to address the research questions on nasopharyngeal carcinoma: The case for an Asian/European partnership
• Emerging therapeutic opportunities in the non coding genome
• Unravelling resistance to multitargeted agents based on high-throughput phosphoproteomics
• Utilizing mutational signatures to inform treatment decisions
• Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sora...

• « Previous
• 1
• 2
• ...
• 119
• Next »